LYSOGENE
Lysogene is a France-based, clinical-stage biopharmaceutical company developing AAV gene therapies for rare pediatric neurodegenerative lysosomal storage diseases, including Sanfilippo Syndrome Type A/B and GM1 Gangliosidosis. It previously traded on Euronext Paris and currently operates with 11-50 employees and no commercial product.
- Company typePrivate
- Founded2009
- HeadquartersNeuilly-sur-seine, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
LYSOGENE firmographics
Firmographics- Name
- LYSOGENE
- Website
- https://lysogene.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 11–50 employees
- Short description
- Lysogene is a France-based, clinical-stage biopharmaceutical company developing AAV gene therapies for rare pediatric neurodegenerative lysosomal storage diseases, including Sanfilippo Syndrome Type A/B and GM1 Gangliosidosis. It previously traded on Euronext Paris and currently operates with 11-50 employees and no commercial product.
- Ownership category
- akta.pro rank
LYSOGENE industry classification
Industry- Product category
- Gene Therapy Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where LYSOGENE is headquartered
LocationHeadquarters
- HQ city
- Neuilly-sur-seine
- HQ country
- France
- HQ region
- Europe
Markets served
LYSOGENE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Others
LYSOGENE product offering
Product offeringCore offering
LYSOGENE is a clinical-stage biopharmaceutical company developing gene therapies for rare, life-threatening neurodegenerative lysosomal storage diseases, with lead programs targeting Sanfilippo Syndrome (MPS IIIA) and GM1 gangliosidosis. The company engineers adeno-associated virus (AAV)-based vectors to deliver therapeutic genes directly to the central nervous system, with the goal of providing disease-modifying, one-time treatments for ultra-rare pediatric conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- LYS-SAF302 (adaglene sulfurase / olenasufilurev)
Companies that use LYSOGENE
Customer profileSegments1 record
Ideal customer profiles2 records
LYSOGENE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LYSOGENE partnerships and signals
Strategic signalScale indicators2 records
LYSOGENE competitors and assessment
Company assessmentBroad incumbents
- uniQure: uniQure is a European-headquartered gene therapy company with an approved AAV product (Hemgenix) and pipeline in CNS and rare metabolic indications. Comparable as a transatlantic AAV platform player with EU regulatory familiarity.
- BioMarin Pharmaceutical: BioMarin is an established rare disease biotech with an approved AAV gene therapy (Roctavian for hemophilia A) and a CNS rare disease franchise. Comparable as a larger commercial-stage rare disease gene therapy developer operating in adjacent genetic disease space.
- Sarepta Therapeutics: Sarepta is a commercial-stage gene therapy company with approved AAV products (Elevidys, Vyondys) and an active CNS/neuromuscular rare disease pipeline. Comparable as a larger player in AAV-delivered rare disease therapeutics.
- REGENXBIO: REGENXBIO develops AAV gene therapies across multiple rare disease indications including CNS (MPS I, MPS II) and partners its NAV technology platform widely. Comparable as a platform AAV developer with overlapping CNS lysosomal storage disorder ambitions.
- Ultragenyx Pharmaceutical: Ultragenyx develops therapeutics for rare and ultra-rare genetic diseases including MPS VII and other lysosomal storage disorders, using both ERT and gene therapy modalities. Comparable as a commercial-stage rare disease specialist with overlapping LSD focus.
Direct peers
- Passage Bio: Passage Bio is a clinical-stage AAV gene therapy company focused on CNS disorders of childhood, including GM1 Gangliosidosis — a direct lead indication overlap with Lysogene. Small, recently restructured, similar clinical-stage footprint.
- Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies for CNS and neurodegenerative disorders using novel capsid and delivery technologies. Directly comparable in modality and target organ (CNS) to Lysogene.
- Taysha Gene Therapies: Taysha Gene Therapies is a clinical-stage AAV gene therapy company developing treatments for CNS monogenic diseases using intrathecal AAV9 delivery. Directly comparable in modality, indication category, and clinical stage to Lysogene.
- Prevail Therapeutics (acquired by Eli Lilly): Prevail developed AAV9 gene therapies for neurodegenerative diseases including GM1 and GM2 gangliosidosis, directly overlapping Lysogene's lead programs. Acquired by Lilly in 2021, illustrating both strategic value and exit dynamics for Lysogene-style assets.
- Abeona Therapeutics: Abeona Therapeutics develops AAV-based gene therapies for rare diseases, most notably MPS IIIA (Sanfilippo Syndrome Type A) — Lysogene's lead indication. It is the most direct competitor and uses the same intrathecal AAV delivery approach.
Market position
Customer concentration
LYSOGENE social profiles
Digital presenceLYSOGENE financial estimates
Financial estimateRevenue estimate
Valuation estimate
LYSOGENE leadership team
Management profileNumber of profiles
Profiles5 records
LYSOGENE funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LYSOGENE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LYSOGENE
What does LYSOGENE do?
LYSOGENE is a clinical-stage biopharmaceutical company developing gene therapies for rare, life-threatening neurodegenerative lysosomal storage diseases, with lead programs targeting Sanfilippo Syndrome (MPS IIIA) and GM1 gangliosidosis. The company engineers adeno-associated virus (AAV)-based vectors to deliver therapeutic genes directly to the central nervous system, with the goal of providing disease-modifying, one-time treatments for ultra-rare pediatric conditions.
When was LYSOGENE founded?
LYSOGENE was founded in 2009. It employs 11 to 50 people.
Where is LYSOGENE based?
LYSOGENE is headquartered in Neuilly-sur-seine, France, in the Europe region.
Who are LYSOGENE's main competitors?
Broad incumbents on record are uniQure, BioMarin Pharmaceutical, Sarepta Therapeutics, REGENXBIO and Ultragenyx Pharmaceutical. Direct peers are Passage Bio, Voyager Therapeutics, Taysha Gene Therapies, Prevail Therapeutics (acquired by Eli Lilly) and Abeona Therapeutics.
Does LYSOGENE have an API?
No public API is recorded for LYSOGENE.
What industry is LYSOGENE in?
LYSOGENE's product category is Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.